EMA Committee Begins Safety Review of Depression Drug and Immunoglobulin Batches

The European Medicines Agency's PRAC has started reviewing Deanxit for depression and anxiety due to reports of serious neurological and psychiatric side effects. Concurrently, a safety signal for increased hypersensitivity reactions with specific batches of human normal immunoglobulin medicines is also under review. This action highlights ongoing pharmacovigilance to ensure drug safety in the EU.